CAS 1661845-86-8

Formule : C21H16ClN3OS

InChI : InChI=1S/C21H16ClN3OS/c1-13-2-7-16(19(22)10-13)18-11-23-9-8-17(18)20-12-24-21(27-20)25-14-3-5-15(26)6-4-14/h2-12,26H,1H3,(H,24,25)

Code InChI : QYDBOFPHPMYWDO-UHFFFAOYSA-N

SMILES : CC1=CC(=C(C=C1)C2=C(C=CN=C2)C3=CN=C(S3)NC4=CC=C(C=C4)O)Cl

CRT-0105950

CAS : 1661845-86-8

CRT-0105950

Formule : C₂₁H₁₆ClN₃OS

Degré de pureté : ≥98%

Masse moléculaire : 393.89

Ref: 54-BUP02721

4-((5-(3-(2-Chloro-4-methylphenyl)pyridin-4-yl)thiazol-2-yl)amino)phenol

CAS : 1661845-86-8

Formule : C₂₁H₁₆ClN₃OS

Degré de pureté : 98%

Masse moléculaire : 393.8892

Ref: IN-DA01ENHQ

CRT0105950

CAS : 1661845-86-8

4-((5-(3-(2-Chloro-4-methylphenyl)pyridin-4-yl)thiazol-2-yl)amino)phenol

Formule : C₂₁H₁₆ClN₃OS

Degré de pureté : 98%

Masse moléculaire : 393.89

Ref: IN-DG01484825

CRT-0105950

CAS : 1661845-86-8

CRT-0105950 is a novel small-molecule drug that sensitizes ovarian cancer cells to cisplatin. CRT-0105950 binds to the miR-200 family of microRNAs and inhibits their function. CRT-0105950 has been shown to increase the sensitivity of ovarian tumor cells in vitro and in vivo to cisplatin, with no evidence of toxicity. The mechanism by which CRT-0105950 enhances cisplatin cytotoxicity is not yet known but may involve modulation of the cell cycle or suppression of tumor growth factors. This drug also has potential applications in monitoring ovarian cancer patients during chemotherapy and for determining the phenotype of cancer cells.

Formule : C₂₁H₁₆ClN₃OS

Degré de pureté : Min. 95%

Masse moléculaire : 393.9 g/mol

Ref: 3D-LRC84586

CRT-0105950

CAS : 1661845-86-8

CRT-0105950 is an effective LIMK inhibitor that acts by suppressing cofilin phosphorylation and increasing αTubulin acetylation in cells.

Formule : C₂₁H₁₆ClN₃OS

Degré de pureté : 99.78% - 99.91%

Couleur et forme : Solid

Masse moléculaire : 393.889

Ref: TM-T23917